维奈克拉联合阿扎胞苷治疗急性髓系白血病的近期疗效:单中心经验
回顾性分析北京大学血液病研究所60例初治不适合强化疗及复发/难治急性髓系白血病患者,接受维奈克拉联合阿扎胞苷治疗。初治不适合强化疗组第1疗程完全缓解/血细胞计数未完全恢复的完全缓解率为70.8%,总体反应率83.3%;复发/难治组分别为58.3%和66.7%。低危复发/难治组完全缓解/血细胞计数未完全恢复的完全缓解率83.3%显著高于高危组45.8%(P=0.031)。
要点
- 初治不适合强化疗组第1疗程完全缓解/血细胞计数未完全恢复的完全缓解率70.8%,总体反应率83.3%。
- 复发/难治组第1疗程完全缓解/血细胞计数未完全恢复的完全缓解率58.3%,总体反应率66.7%。
- 低危复发/难治组完全缓解/血细胞计数未完全恢复的完全缓解率83.3%显著高于高危组45.8%(P=0.031)。
核心结论
- 维奈克拉联合阿扎胞苷在初治不适合强化疗及复发/难治急性髓系白血病患者中均获得较高的治疗反应率,部分患者可快速获得微小残留病转阴。
- 其在伴NPM1、IDH1/2、TP53等基因突变的急性髓系白血病患者中疗效显著,长期疗效尚待观察。
研究设计与样本
- 回顾性研究,纳入北京大学血液病研究所2019年6月1日至2021年5月31日接受维奈克拉联合阿扎胞苷治疗的初治不适合强化疗及复发/难治急性髓系白血病患者60例。
- 给药方案为维奈克拉100 mg第1天、200 mg第2天、400 mg第3~28天;阿扎胞苷75 mg/m(2)第1~7天。
主要发现
- 60例患者中位年龄54(18~77)岁,男性33例(55.0%),中位随访时间4.8(1.4~26.3)个月;初治不适合强化疗组24例(40.0%),复发/难治组36例(60.0%)。
- 初治不适合强化疗组第1疗程后17/24(70.8%)达完全缓解/血细胞计数未完全恢复的完全缓解,3/24(12.5%)达部分缓解,总体反应率83.3%;17例完全缓解/血细胞计数未完全恢复的完全缓解患者中8/17(47.1%)经2个疗程后微小残留病转阴。
- 复发/难治组第1疗程后21/36(58.3%)达完全缓解/血细胞计数未完全恢复的完全缓解(其中7/21微小残留病转阴),3例部分缓解,总体反应率66.7%;12例治疗≥2个疗程,第2疗程后无新增缓解,累计微小残留病转阴14例(66.7%)。
- 低危复发/难治组(完全缓解至血液学复发≥18个月)12例中10例(83.3%)第1疗程后达完全缓解/血细胞计数未完全恢复的完全缓解,显著高于高危复发/难治组的45.8%(11/24)(P=0.031)。
- 13例伴IDH1/2突变及4例TP53阳性患者经1个疗程后均达完全缓解/血细胞计数未完全恢复的完全缓解;18例NPM1突变阳性患者1个疗程完全缓解/血细胞计数未完全恢复的完全缓解率为77.8%;5例RUNX1-RUNX1T1伴KIT D816突变患者(2例初诊、3例复发)均未获缓解。
关键数值与推荐
- 初治不适合强化疗组第1疗程完全缓解/血细胞计数未完全恢复的完全缓解率70.8%(17/24),部分缓解率12.5%(3/24),总体反应率83.3%。
- 复发/难治组第1疗程完全缓解/血细胞计数未完全恢复的完全缓解率58.3%(21/36),部分缓解率8.3%(3/36),总体反应率66.7%。
- 低危复发/难治组完全缓解/血细胞计数未完全恢复的完全缓解率83.3%(10/12)vs 高危复发/难治组45.8%(11/24),P=0.031。
临床怎么用
- 维奈克拉联合阿扎胞苷作为诱导及再诱导治疗总体耐受性好。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the safety and short-term efficacy of venetoclax combined with azacitidine (Ven+AZA) in previously untreated patients unfit for standard chemotherapy and patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) in China. Methods: A retrospective study was conducted in 60 previously untreated patients unfit for standard chemotherapy and patients with R/R AML who received Ven+ AZA (venetoclax, 100 mg D1, 200 mg D2, 400 mg D3-28; azacitidine, 75 mg/m(2) D1- 7) at the Peking University Institute of Hematology from June 1, 2019 to May 31, 2021. The incidence of adverse events, complete remission (CR) /CR with incomplete hematological recovery (CRi) rate, objective remission rate (ORR) , and minimal residual disease (MRD) status in patients with different risk stratification and gene subtypes were analyzed. Results: The median age of the patients was 54 (18-77) years, 33 (55.0%) were males, and the median follow-up time was 4.8 (1.4-26.3) months. Among the 60 patients, 24 (40.0%) were previously untreated patients unfit for standard chemotherapy, and 36 (60.0%) were R/R patients. The median mumber cycles of Ven+AZA in the two groups were both 1 (1-5) . According to the prognostic risk stratification of the National Comprehensive Cancer Network, it was divided into 8 cases of favorable-risk, 2 cases of intermediate risk, and 14 cases of poor-risk. In previously untreated patients unfit for standard chemotherapy, after the first cycle of Ven+AZA, 17/24 (70.8%) cases achieved CR/CRi, 3/24 (12.5%) achieved partial remission (PR) , and the ORR was 83.3%. Among them, nine patients received a second cycle chemotherapy and two received a third cycle. Among CR/CRi patients, 8/17 (47.1%) achieved MRD negativity after two cycles of therapy. In the R/R group, after the first cycle of Ven+AZA, 21/36 (58.3%) cases achieved CR/CRi (7/21 achieved MRD negativity) , 3 achieved PR, and the ORR was 66.7%. Among R/R patients, 12 were treated for more than two cycles. There were no new CR/CRi patients after the second treatment cycle, and 14 cases (66.7%) achieved MRD negativity. According to the time from CR to hematological recurrence, the R/R group was divided into 12 cases in the favorable-risk group (CR to hematological recurrence ≥18 months) and 24 in the poor-risk group (CR to hematological recurrence<18 months, no remission after one cycle of therapy, and no remission after two or more cycles of therapy) . Eleven of 24 (45.8%) cases achieved CR/CRi after one cycle of Ven+AZA in the poor-risk R/R group, and 10 of 12 (83.3%) achieved CR/CRi in the favorable-risk R/R group, which was significantly superior to the poor-risk group (P=0.031) . After one cycle of treatment, 13 patients with IDH1/2 mutations and 4 that were TP53-positive all achieved CR/CRi. The CR/CRi rate of 18 patients with NPM1 mutations was 77.8%. Five patients with RUNX1-RUNX1T1 combined with KIT D816 mutation (two initial diagnoses and three recurrences) had no remission. Ven+ AZA was tolerable for AML patients. Conclusion: Ven+AZA has acceptable safety in previously untreated patients unfit for standard chemotherapy, patients with R/R AML can achieve a high response rate, and some patients can achieve MRD negativity. It is also effective in NPM1-, IDH1/IDH2-, and TP53-positive patients. The long-term efficacy remains to be observed. 目的: 探究维奈克拉联合阿扎胞苷(Ven+AZA)在初治不适合强化疗(unfit)及难治(≥1次强化诱导化疗未缓解)/复发(R/R)急性髓系白血病(AML)患者中的近期疗效。 方法: 回顾性分析北京大学血液病研究所2019年6月1日至2021年5月31日接受Ven+AZA治疗(Ven 100 mg第1天、200 mg第2天、400 mg第3~28天;阿扎胞苷75 mg/m(2)第1~7天)的初治unfit及R/R AML患者60例。分析各组完全缓解/血细胞计数未完全恢复的完全缓解(CR/CRi)率、微小残留病(MRD)转阴率及总体反应率(ORR)。 结果: 60例初治unfit及R/R AML患者,中位年龄54(18~77)岁,男性33例(55.0%),中位随访时间4.8(1.4~26.3)个月。其中初治unfit患者24例(40.0%),R/R患者36例(60.0%)。初治unfit组及R/R组中位治疗疗程均为1(1~5)个。24例初治unfit患者(依据NCCN预后分层:低危8例、中危2例、高危14例)经第1疗程Ven+AZA治疗后,17例(70.8%)达CR/CRi,3例(12.5%)达部分缓解(PR),ORR为83.3%。其中9例患者接受第2疗程治疗,2例接受第3疗程治疗。17例CR/CRi患者中8例(47.1%)经2个疗程治疗后MRD转阴。36例R/R患者经第1疗程诱导治疗后,21例(58.3%)达CR/CRi(其中7例MRD转阴,占33.3%),3例(8.3%)PR,ORR为66.7%。R/R患者中12例治疗≥2个疗程,第2疗程治疗后无新增缓解患者,累计MRD转阴14例(66.7%)。R/R患者中低危组(CR至血液学复发≥18个月)12例,其余24例为高危组。低危R/R组1个疗程后10例(83.3%)达CR/CRi,CR/CRi率显著高于高危R/R组[45.8%(11/24),P=0.031]。在60例患者中,13例伴IDH1/2突变及4例TP53阳性患者经1个疗程治疗后均达CR/CRi,18例NPM1突变阳性患者1个疗程CR/CRi率为77.8%,5例RUNX1-RUNX1T1伴c-kit D816患者(2例初诊,3例复发)均未获缓解。Ven+AZA作为诱导及再诱导治疗总体耐受性好。 结论: Ven+AZA在初治unfit及R/R AML患者中均获得较高的治疗反应率,部分缓解患者可快速获得MRD转阴。其在伴NPM1、IDH1/2、TP53等基因突变的AML患者中疗效显著。.
引用
- Yu WJ, Jia JS, Wang J, et al. [Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience]. Zhonghua Xue Ye Xue Za Zhi. 2022. PMID: 35381674. doi:10.3760/cma.j.issn.0253-2727.2022.02.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。